(MENAFN- News Direct) Detroit, Michigan | November 23, 2022 11:20 AM Eastern Standard Time
Sunshine Biopharma (NASDAQ: SBFM) has entered into a collaboration agreement with one of North America's leading lipid nanoparticle ('LNP') formulation companies to advance the development of Sunshine Biopharma's mRNA-based anticancer macromolecule, K1.1! Learn more about this collaboration and its significance in this video! Sunshine Biopharma focuses on the research, development & commercialization of life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. Visit Sunshine Biopharma:
MENAFN24112022005728012573ID1105226390
Legal Disclaimer:
MENAFN provides the information βas isβ without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.